Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data
CONCLUSION: The incidence and prevalence rates of MG are significantly higher than those previously reported in the literature and the incidence increases with age. The excess risk of cancer raises concerns for MG patients, in particular, concerning the management of immunosuppressive drugs.PMID:38582663 | DOI:10.1016/j.neurol.2024.02.392
Source: Revue Neurologique - Category: Neurology Authors: S Keovilayhong A Mulliez L Feral C Chenaf P Clavelou X Moisset F Taithe L Poncet Megemont Source Type: research
More News: Autoimmune Disease | Brain | Cancer | Cancer & Oncology | Databases & Libraries | Epidemiology | France Health | Health Insurance | Insurance | Myasthenia Gravis | Neurology | Study | Thyroid | Thyroid Cancer | Women